Pharma News

In recent years, in the global wave of innovation in pharmaceutical research and development, a new drug named "orexin receptor antagonist" has gradually emerged and become a research hotspot.

Recently, the journal Nature Reviews Microbiology published a research report that thoroughly analyzed the development process of malaria vaccines and their effectiveness and challenges.

In the field of cancer treatment, a landmark breakthrough has been achieved with the recent approval from the U.S. Food and Drug Administration (FDA) for the commercial application of lifileucel.

This news is like a spring breeze, injecting new vitality into the stock prices of Stonepeak and Arvida, pushing Arvida's share price to soar nearly 60% on Monday, reaching a new high in more than two years.

On September 17th, the iconic logo of the American pharmaceutical giant Eli Lilly shone brightly at the company's office complex in San Diego, California, revealing an important industry development.

The U.S. Centers for Disease Control and Prevention (CDC) announced last Friday that two additional H5N1 avian flu cases have been detected on poultry farms in Colorado.

The global antimicrobial coatings market is forecast to surpass $10.1 billion by 2032, primarily driven by the increasing focus on hygiene standards and the growing demand for antimicrobial solutions.

Johnson & Johnson, the world's leading healthcare company, recently released its financial results for the first half of 2024, demonstrating its solid growth in a complex healthcare market environment.

Boehringer Ingelheim delivered a solid business performance in the first half of 2024, achieving a significant increase in net sales, up 7.4% year-on-year to €12.9 billion.

China's leading radiation therapy company has signed a global licensing agreement worth $571.5 million with South Korean biotech giant SKBiopharmaceuticals, marking a solid step in the two companies' collaboration in the field of cancer treatment.

The power of the market is like an invisible giant hand, quietly affecting the rise and fall of every industry.

Global technology giant Nvidia's layout in the field of AI pharmaceuticals has once again attracted attention, this time, it has chosen to join forces with the world's leading pharmaceutical company Pfizer to jointly invest in Israeli startup CytoReason.

The global pharmaceutical industry has recently witnessed a number of compelling developments that demonstrate not only the innovation of the industry, but also the efforts of companies to address market challenges and meet patient needs.

China Resources Boyalife announced on July 19, 2024 that it will fully acquire the entire equity of Green Cross Hong Kong Holdings Limited held by GC Group for a transaction value of 18.2 billion yuan.

Eisai and Japan's Sato Pharmaceutical have announced a major collaboration, entering into a licensing agreement for the development and marketing rights of the novel antifungal drug Fosravuconazole (Fluxacom) in Asia and Oceania.

Recently, AusperBio announced that it has successfully completed A Series A funding round of up to $37 million.

Amid the rapid advances in the frontier of medicine, CAR-T therapy, we are witnessing a dynamic that is both exciting and complex. Recent news reports have revealed some key trends in this field.

On July 16, 2024, the news of China ZaiLab announced that the national drug supervision and administration (NMPA) has approved the new biological products and wale ®'s application for marketing authorisation.

Recently, the Swiss pharmaceutical giant roche said, it is in the study of new type of glp-1 / GIP double agonist CT - 388 performance is satisfactory in phase I clinical trials, the results present a positive trend.

Mabwell (stock code: 688062.SH), as an innovative company in the field of bioparmaceuticals, has announced an important news.